292 related articles for article (PubMed ID: 25496450)
1. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
4. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
5. A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.
Lapini A; Minervini A; Masala A; Schips L; Pycha A; Cindolo L; Giannella R; Martini T; Vittori G; Zani D; Bellomo F; Cosciani Cunico S
Surg Endosc; 2012 Dec; 26(12):3634-41. PubMed ID: 22729704
[TBL] [Abstract][Full Text] [Related]
6. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
8. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Pagliarulo V; Alba S; Gallone MF; Di Stasi S; Cormio L; Petitti T; Buscarini M; Minafra P; Carrieri G
J Endourol; 2017 Apr; 31(4):405-411. PubMed ID: 28145751
[TBL] [Abstract][Full Text] [Related]
10. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
Geavlete B; Multescu R; Georgescu D; Geavlete P
J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
12. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
[TBL] [Abstract][Full Text] [Related]
14. [Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].
Burgués JP; Conde G; Oliva J; Abascal JM; Iborra I; Puertas M; Ordoño F;
Actas Urol Esp; 2011 Sep; 35(8):439-45. PubMed ID: 21621301
[TBL] [Abstract][Full Text] [Related]
15. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
[TBL] [Abstract][Full Text] [Related]
16. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
[TBL] [Abstract][Full Text] [Related]
18. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
[TBL] [Abstract][Full Text] [Related]
19. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
20. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
